Signal transduction inhibitors and antiangiogenic therapies for malignant glioma (Q37847104)

24 August 2017

1 reference

title

Signal transduction inhibitors and antiangiogenic therapies for malignant glioma (English)

1 reference

24 August 2017

main subject

angiogenesis inhibitor

1 reference

3

Patrick Y Wen

1 reference

24 August 2017

Ingo K Mellinghoff

1

1 reference

24 August 2017

Andrew B Lassman

series ordinal

2

1 reference

24 August 2017

publication date

23 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

59

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

1205-1212

1 reference

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Positive and negative modulation of angiogenesis by VEGFR1 ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Antiangiogenic strategies for treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Essential role for oncogenic Ras in tumour maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Emerging antiangiogenic treatments for gliomas - efficacy and safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Reversible tumorigenesis by MYC in hematopoietic lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Malignant astrocytic glioma: genetics, biology, and paths to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Gefitinib concentrations in human glioblastoma tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Bevacizumab for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

The role of PTEN signaling perturbations in cancer and in targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Antiangiogenic therapies for high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Shifting paradigms: the seeds of oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

The new era in cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Epidermal growth factor receptor and Ink4a/Arf

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

7 January 2021

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

7 January 2021

Targeting multiple kinases in glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

7 January 2021

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21137

7 January 2021

Identifiers

DOI

10.1002/GLIA.21137

1 reference

release_tntlhlpfyrd3rntz5zazu65ara

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tntlhlpfyrd3rntz5zazu65ara

24 November 2022

mapped directly with Wikidata item

1 reference